Division of Metabolism and Children's Research Center, University Children's Hospital, Zürich, Switzerland.
radiz-Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland.
J Inherit Metab Dis. 2019 Mar;42(2):333-352. doi: 10.1002/jimd.12041. Epub 2019 Feb 17.
To explore the clinical presentation, course, treatment and impact of early treatment in patients with remethylation disorders from the European Network and Registry for Homocystinurias and Methylation Defects (E-HOD) international web-based registry.
This review comprises 238 patients (cobalamin C defect n = 161; methylenetetrahydrofolate reductase deficiency n = 50; cobalamin G defect n = 11; cobalamin E defect n = 10; cobalamin D defect n = 5; and cobalamin J defect n = 1) from 47 centres for whom the E-HOD registry includes, as a minimum, data on medical history and enrolment visit. The duration of observation was 127 patient years. In 181 clinically diagnosed patients, the median age at presentation was 30 days (range 1 day to 42 years) and the median age at diagnosis was 3.7 months (range 3 days to 56 years). Seventy-five percent of pre-clinically diagnosed patients with cobalamin C disease became symptomatic within the first 15 days of life. Total homocysteine (tHcy), amino acids and urinary methylmalonic acid (MMA) were the most frequently assessed disease markers; confirmatory diagnostics were mainly molecular genetic studies. Remethylation disorders are multisystem diseases dominated by neurological and eye disease and failure to thrive. In this cohort, mortality, thromboembolic, psychiatric and renal disease were rarer than reported elsewhere. Early treatment correlates with lower overall morbidity but is less effective in preventing eye disease and cognitive impairment. The wide variation in treatment hampers the evaluation of particular therapeutic modalities.
Treatment improves the clinical course of remethylation disorders and reduces morbidity, especially if started early, but neurocognitive and eye symptoms are less responsive. Current treatment is highly variable. This study has the inevitable limitations of a retrospective, registry-based design.
通过欧洲同型胱氨酸尿症和甲基化缺陷网络和登记处(E-HOD)国际网络登记处,探讨 remethylation 障碍患者的临床表现、病程、治疗方法和早期治疗的影响。
本综述纳入了来自 47 个中心的 238 名患者(钴胺素 C 缺陷 161 例;亚甲基四氢叶酸还原酶缺乏症 50 例;钴胺素 G 缺陷 11 例;钴胺素 E 缺陷 10 例;钴胺素 D 缺陷 5 例;钴胺素 J 缺陷 1 例),E-HOD 登记处至少包括患者的病史和入组就诊数据。观察时间为 127 个患者年。在 181 例临床诊断的患者中,发病时的中位年龄为 30 天(范围为 1 天至 42 岁),诊断时的中位年龄为 3.7 个月(范围为 3 天至 56 岁)。75%的临床诊断为钴胺素 C 疾病的隐匿性患者在生命的前 15 天内出现症状。同型半胱氨酸(tHcy)、氨基酸和尿甲基丙二酸(MMA)是最常评估的疾病标志物;主要的确诊诊断方法是分子遗传学研究。Remethylation 障碍是一种多系统疾病,以神经和眼部疾病以及生长不良为主要表现。在本队列中,死亡率、血栓栓塞、精神疾病和肾脏疾病比其他地方报道的更为罕见。早期治疗与整体发病率降低相关,但对预防眼部疾病和认知障碍的效果较差。治疗方法的广泛差异阻碍了对特定治疗方式的评估。
治疗可以改善 remethylation 障碍的临床病程,降低发病率,尤其是在早期开始治疗时,但神经认知和眼部症状的反应较差。目前的治疗方法差异很大。本研究存在回顾性、基于登记的设计不可避免的局限性。